Ose Immunotherapeutics
OSE.PA operates in the healthcare diagnostics industry, providing products and services related to medical testing and diagnostic solutions.
Business. OSE.PA is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm generates revenue through product sales and is primarily listed on the Euronext Paris exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
Analyst recommendations
4 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
OSE.PA is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm generates revenue through product sales and is primarily listed on the Euronext Paris exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
OSE.PA has a negative operating cash flow of -34 million EUR and a net loss of -37.4 million EUR, indicating significant liquidity and profitability challenges. The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents. The valuation snapshot does not provide additional clarity on the company's financial health, as no custom valuations are available for further analysis.
The company's operating income is -37.5 million EUR, and its net income is -37.4 million EUR, both of which are negative and suggest poor profitability. These figures are not directly comparable to industry medians due to the lack of industry_config data for this specific industry. The company's financial performance is a concern, as it is not generating positive returns or margins.
OSE.PA's revenue is concentrated in a single entity, with no disclosed segments or geographic breakdown. This lack of diversification increases the company's exposure to market-specific risks and limits visibility into its operational performance across different regions or product lines.
The company's growth trajectory is unclear, as no outlook data is available for the current or next fiscal year. The absence of revenue history beyond the most recent period makes it difficult to assess the company's growth potential or performance trends. Analysts have provided a mean price target of 10.60 EUR, with a median of 10.60 EUR, suggesting a neutral to slightly positive outlook, but the mean recommendation of 1.75 indicates a mixed sentiment among analysts.
The company's risk profile includes a low dilution potential, but the liquidity risk remains unassessed due to the lack of balance-sheet data. The absence of going-concern language in the source documents raises concerns about the company's ability to continue operations without additional financing. No recent events or filings have been disclosed that would provide further insight into the company's strategic direction or operational changes.
- OSE.PA is experiencing significant financial losses, with a net loss of -37.4 million EUR and a negative operating cash flow of -34 million EUR.
- The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents.
- Analysts have provided a mean price target of 10.60 EUR, with a median of 10.60 EUR, indicating a neutral to slightly positive outlook.
- The company's financial performance is a concern, as it is not generating positive returns or margins.
- OSE.PA's revenue is concentrated in a single entity, with no disclosed segments or geographic breakdown, increasing its exposure to market-specific risks.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,98 |
| Revenue | —no estimate | —no estimate | 8,9M EUR |
| Operating income | —no estimate | —no estimate | -23,5M EUR |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Cash Conversion Ratiooperating_cash_flow / net_income
- OSE.PA Market data — financials · 2026-05-28
- OSE Immunotherapeutics SA Market data — analyst estimates · 2026-05-28